Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated (NASDAQ: CORT) concerning potential violations of the federal securities laws.
August 2020, Teva Pharmaceutical Industries Limited ("Teva") received approval from the U.S. Food and Drug Administration to market an off-patent version of Korlym, a best-selling Corcept product. Then on February 20, 2025, Seeking Alpha reported that a group of health insurers had filed a lawsuit against Corcept in California, accusing Corcept of manipulating the patent process in its efforts to "vigorously enforce" its intellectual property rights linked to Korlym, in an effort to stifle Teva's generic product launch. Following this news, Corcept's stock price fell over 11% on the same day.
If you suffered a loss on your Corcept Therapeutics Incorporated securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





